Abstract
Scientific Reports 6: Article number: 34053; published online: 11 October 2016; updated: 29 November 2016
Highlights
In the Abstract, “Subsequently, grafting of arginine-glycine-aspartic acid peptide on the surface of nanocarrier (CPMSN) thwarted the uptake by normal cells, but facilitated their uptake in cancer cells through integrin receptor mediated endocytosis and the dissociation of nanocarriers due to the ability to degrade of CS and PAA in acidic pH, which enhance the intracellular release of drugs”
Reads: “Subsequently, grafting of arginine-glycine-aspartic acid peptide on the surface of nanocarrier (CPMSN) thwarted the uptake by normal cells, but facilitated their uptake in cancer cells through integrin receptor mediated endocytosis and the dissociation of nanocarriers due to the ability to degrade CS and PAA in acidic pH, which enhance the intracellular release of drugs”
In the same section under subheading ‘Analysis of Δψm loss and nuclear morphology by fluorescence microscopy’, “It was observed that the growth of cells was inhibited when they were treated with free TPT, free QT, free TPT+QT, TPT-MSN-NH2-PAA-CS-QT, and CPMSNs at their final concentrations (2 μg/mL), and the CPMSNs possess higher antiproliferative efficacy against cancer cells than free drugs”
Summary
OPEN Corrigendum: Combinatorial nanocarrier based drug delivery approach for amalgamation of anti-tumor agents in breast cancer cells: an improved nanomedicine strategy The Title, “Combinatorial nanocarrier based drug delivery approach for amalgamation of anti-tumor agents in bresat cancer cells: an improved nanomedicine strategies”.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
